ACTIVE

Gulliver Biomed

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result56,9 k €+5,5 %over 1 year
Gross margin96,2 k €+32,7 %over 1 year
Equity131,6 k €+76,1 %over 1 year

Identity

Source · BCE/KBO

Gulliver Biomed is a Private limited company incorporated in 2018. Its main activity is: Technical testing and analysis. Its registered office is in Gent.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0692.527.837
Incorporation
14/03/2018
Legal form
Private limited company
Registered office
Technologiepark-Zwijnaarde 82
9052 Gent · FlandreSee on map
Contributed capital
18 600,00 €
Latest accounts
31/12/2025
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA

Financials

Source · NBB, 8 filings

Trend over 8 financial years

20252024202320222021
Income statement
Gross margin96,2 k €72,5 k €516,6 €34,5 k €9,8 k €
EBITDA95,2 k €71,9 k €0,4 €34 k €9,3 k €
Operating result85,6 k €62,3 k €-9,9 k €29 k €8,6 k €
Net result56,9 k €53,9 k €-11,4 k €21,8 k €6,2 k €
Balance sheet
Equity131,6 k €74,8 k €20,8 k €78,3 k €51,1 k €
Total assets258,1 k €116,6 k €105 k €127 k €62,3 k €
Cash111,6 k €86,5 k €652 €67,2 k €48,6 k €
Debts126,4 k €40,9 k €83,5 k €48,4 k €11,2 k €

Valuation

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 4 ended

Active mandates

Jan Christiaan Gettemans

Director · since 13 juillet 2023

Active

Ended mandates

Jan Gettemans

Director · since 13 mars 2018

Ended
Jan Christiaan Gettemans

Director

Ended
Jan Gettemans

Director

Ended
Jan Gettemans

Manager

Ended

Other companies at this address

Technologiepark-Zwijnaarde 82 9052 Gent
CompanyCBE no.
Amalus Therapeutics● Bankrupt
0803.929.268
APCOR R&M● Active
0600.952.909
Ardoyen● Active
0875.102.821
AVROXA● Active
0687.774.936
Benebiose● Active
0784.521.548
BioNeering● Active
0807.194.309
CONTREL EUROPE● Active
0426.204.637
CRODEON TECHNOLOGIES● Active
0642.754.761
Cryptobiotix● Active
0762.565.104
ImplicitMeasures.com● Bankrupt
0657.989.701
Inbiose● Active
0534.887.593
INCUBATIE- EN INNOVATIECENTRUM UNIVERSITEIT● Active
0440.054.752
INNOVATIVE PHARMACEUTICS● Active
0883.574.582
Inspect● Active
0645.950.417
INVIBES ADVERTISING● Active
0836.533.938
KYTOS● Active
0768.755.286
Lares Solutions● Active
1015.346.906
MAYAKU PHARMACEUTICAL DEVELOPMENT● Active
0755.350.975
Microbial Resource Management Health● Active
0742.910.132
Microbial Resource Management Technologies● Active
0667.765.816

Full financial information

Source · NBB
202520242023202220212020
Type of accountMicro modelMicro modelMicro modelMicro modelMicro modelMicro model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date15/09/202630/09/202530/10/202406/07/202320/06/202215/06/2021
General meeting10/09/202630/09/202530/10/202430/06/202310/06/202211/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 8 filings
ModelClosingGeneral meetingFiledLanguageDocument
Micro model31/12/202510/09/202615/09/2026DutchPDF
Micro model31/12/202430/09/202530/09/2025DutchPDF
Micro model31/12/202330/10/202430/10/2024DutchPDF
Micro model31/12/202230/06/202306/07/2023DutchPDF
Micro model31/12/202110/06/202220/06/2022DutchPDF
Micro model31/12/202011/06/202115/06/2021DutchPDF
Micro model31/12/201912/06/202003/07/2020DutchPDF
Micro model31/12/201828/06/201904/07/2019DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 4 ended

Active mandates

Jan Christiaan Gettemans

Director · since 13 juillet 2023

Active

Ended mandates

Jan Gettemans

Director · since 13 mars 2018

Ended
Jan Christiaan Gettemans

Director

Ended
Jan Gettemans

Director

Ended
Jan Gettemans

Manager

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates20/07/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - WIJZIGING RECHTSVORM - DIVERSEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Registered office21/01/2019
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Other16/03/2018
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 202556,9 k €↑
  2. 2024
    Annual accounts 202453,9 k €↑
  3. 2023
    Annual accounts 2023-11,4 k €↓
  4. 2022
    Annual accounts 202221,8 k €↑
  5. 2021
    Annual accounts 20216,2 k €↓
  6. 2020
    Annual accounts 202027,4 k €↑
  7. 2019
    Annual accounts 20198,8 k €↑
  8. 2018
    Annual accounts 2018-3,8 k €
  9. 14/03/2018
    IncorporationPrivate limited company